In a monumental step forward for global public health, Indian pharmaceutical companies Dr Reddy’s Laboratories and Hetero Labs have announced they will produce and sell generic versions of a revolutionary HIV prevention drug. It will be available for around $40 per year. Availability is expected from 2027. The drug, lenacapavir, is a long-acting injectable developed by Gilead Sciences. It has…